MIR26A1

Summary

MIR26A1 (microRNA 26a-1, HGNC:31610) is a microRNA gene on chromosome 3p22.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407015 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31610
Approved symbol	MIR26A1
Name	microRNA 26a-1
Location	3p22.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-26a-1
Ensembl gene	ENSG00000199075
Ensembl biotype	miRNA
OMIM	612151
Entrez	407015
RNAcentral	URS000023C301 — miRNA, 77 nt, 37 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362205

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362205 — 1 exons

Exon	Start	End
ENSE00001436968	37969404	37969480

Expression profiles

Bgee: expression breadth broad, 87 present calls, max score 93.81.

Top tissues by expression

87 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	93.81	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.90	gold quality
blood	UBERON:0000178	81.84	gold quality
prefrontal cortex	UBERON:0000451	77.88	gold quality
placenta	UBERON:0001987	77.62	gold quality
calcaneal tendon	UBERON:0003701	73.12	gold quality
right atrium auricular region	UBERON:0006631	72.40	gold quality
heart left ventricle	UBERON:0002084	71.59	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	70.88	gold quality
heart	UBERON:0000948	70.74	gold quality
body of pancreas	UBERON:0001150	70.35	gold quality
endometrium	UBERON:0001295	70.15	gold quality
tibial artery	UBERON:0007610	70.00	gold quality
popliteal artery	UBERON:0002250	69.95	gold quality
gastrocnemius	UBERON:0001388	69.87	gold quality
liver	UBERON:0002107	69.84	gold quality
left adrenal gland cortex	UBERON:0035825	69.23	gold quality
skin of abdomen	UBERON:0001416	68.83	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	68.70	gold quality
lower esophagus muscularis layer	UBERON:0035833	68.21	gold quality
rectum	UBERON:0001052	68.18	gold quality
ascending aorta	UBERON:0001496	68.15	gold quality
left adrenal gland	UBERON:0001234	67.96	gold quality
left coronary artery	UBERON:0001626	67.88	gold quality
thoracic aorta	UBERON:0001515	67.87	gold quality
body of stomach	UBERON:0001161	67.81	gold quality
stomach	UBERON:0000945	67.44	gold quality
zone of skin	UBERON:0000014	67.30	gold quality
gall bladder	UBERON:0002110	67.05	gold quality
transverse colon	UBERON:0001157	66.99	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.20

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA, CLOCK, CREB1, EGR1, FOXC1, TP53

Literature-anchored findings (GeneRIF, showing 40)

• MYC stimulates EZH2 expression by repression of its negative regulator miR-26a (PMID:18713946)
• Zcchc11 fine tunes IL-6 production by uridylating miR-26a. (PMID:19701194)
• In patients with hepatocellular carcinoma, the expression of miR-26a and miR-26b in nontumor liver tissue was higher in women than in men. The miR-26 expression status of patients is associated with survival and response to therapy with interferon alfa. (PMID:19812400)
• Results suggest that miRNAs -26a, -34a, -145, and let-7b may modulate expression of IFN-beta, thereby influencing innate immunity from the earliest responses to viral infection. (PMID:20130213)
• demonstrated a role for miR-26a, miR-145 and miR-26a in TRAIL-induced apoptosis. (PMID:20230625)
• Study unveils that miR-26a is a mechanosensitive gene, and it plays an important role in the regulation of HASMC hypertrophy. (PMID:20525681)
• MiRNA-26a promotes vascular smooth muscle cell proliferation while inhibiting cellular differentiation and apoptosis, and alters TGF-beta pathway signaling. (PMID:20857419)
• miR-26a functionally antagonizes human breast carcinogenesis by targeting MTDH and EZH2. (PMID:20952513)
• RalA interaction with the Exo84 but not Sec5 exocyst component was necessary for supporting anchorage-independent growth, whereas RalB interaction with Sec5 but not Exo84 was necessary for inhibition of anchorage-independent growth (PMID:21199804)
• hAFP-TERT dual promoter-mediated miR-26a expression could specifically exert potential antitumor activity and provide a novel targeting approach for cancer therapy. (PMID:21610700)
• Data indicate that miR-15a, miR-16, miR-26ab, miR-196ab and Let-7a as potential HMGA1 and HMGA2-targeting miRNAs. (PMID:22139073)
• miRNAs (miR-26a1/2 and miR-26b) downregulate BDNF expression and the presence of the variant alleles of two single nucleotide polymorphisms (rs11030100 and rs11030099) mapping in BDNF 3’UTR specifically abrogates miRNAs targeting. (PMID:22194877)
• trastuzumab modulates the expression of a subset of microRNAs, including miR-26a and miR-30b (PMID:22384020)
• Silencing of MEN1 mRNA resulted in a down regulation of miR-26a and chromatin immunoprecipitation showed that menin occupies the miR-26-a gene promoter, thus inducing gene expression. (PMID:22409234)
• miR-26a expression inhibited the expression of enhancer of zeste homolog 2 and transactivated downstream target genes, which suggests that EZH2 is a potential target of miR-26a; miR-26a plays an important role as an anti-oncogene in the molecular mechanism of lung cancer (PMID:22469510)
• Our study demonstrated that miR-26a enhanced lung cancer cell metastasis potential via modulation of metastasis-related gene expression, and activation of AKT pathway by PTEN suppression (PMID:22885155)
• MicroRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells. (PMID:23096114)
• miR-26a may be involved in regulation of anoikis-resistance of esophageal adenocarcinoma cells. (PMID:23108995)
• MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). (PMID:23190898)
• Our investigation of the mechanisms underlying the decrease in miR-26a in this lymphoma revealed novel evidence that STAT3, a major downstream substrate of NPM-ALK tyrosine kinase activity, suppresses MIR26A1 gene expression. (PMID:23338972)
• miR-26a/b and miR-29b are upregulated during osteogenic differentiation of unrestricted somatic stem cells and share target genes inhibiting osteogenesis (PMID:23418963)
• miR-26a and related pathways, such as PRKCD, play an important role in cell cycle control of ACTH pituitary cells, opening new therapeutic possibilities for the treatment of persistent/recurrent Cushing’s disease. (PMID:23525216)
• CHIP assay demonstrated that MYC recruited EZH2 to miR-26a promoter and cooperatively repressed miR-26a expression in aggressive lymphoma cell lines, as well as primary lymphoma cells (PMID:23538750)
• miR-26 controls the expression of KCNJ2 and may have a role in atrial fibrillation (PMID:23543060)
• miR-26a impacts on cell proliferation and migration of breast cancer by regulating several carcinogenesis-related processes, including a novel mechanism involving the targeting of MCL-1 (PMID:23750239)
• MicroRNA-26a regulates prohibitin and promotes glioma progression and angiogenesis. (PMID:23870455)
• data suggest that miR-26a functions as a tumor suppressor in GC development and progression, and holds promise as a prognostic biomarker and potential therapeutic target for GC. (PMID:24015269)
• MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. (PMID:24047927)
• miR-26a directly targets Lin28B and Zcchc11-two critical repressors of let-7 maturation. (PMID:24056962)
• Data indicate that miR-26a overexpression inhibited pancreatic cancer cell growth by the downregulation of cyclin E2 expression. (PMID:24116110)
• Data indicate that expression of miR-1260, -26a, -335*, -576-3p, -628-3p and -664 were consistently dysregulated in both whole blood and H1N1 infected cells. (PMID:24116168)
• c-Myc modulates genes associated with oncogenesis in glioblastoma multiforme through deregulation of miRNAs via the c-Myc-miR-26a-PTEN signaling pathway. (PMID:24140063)
• MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2alpha/Akt/HIF-1alpha pathway in hepatocellular carcinoma. (PMID:24194905)
• miR-26a may act as a new radiosensitizer of glioblastoma multiforme cells. (PMID:24211747)
• miR-26a could suppress tumor angiogenesis of hepatocellular carcinoma (HCC) through HGF-cMet signaling. (PMID:24259426)
• Loss of miR-26a expression is associated with DNA hypermethylation in basal-like breast cancer. (PMID:24297604)
• Circulating miR-26a was reduced in the plasma of both monocrotaline-induced pulmonary hypertension rats and treatment-naive patients with idiopathic pulmonary arterial hypertension compared with healthy control subjects. (PMID:24328779)
• High DNMT3B expression was associated with tongue squamous cell carcinoma. (PMID:24343426)
• miR-26a and -26b were identified as key regulators of human white and brite adipocyte differentiation. (PMID:24375761)
• This study provides further data for the identification of a miRNA profile for glioblastoma and suggests that different-grade neoplasia could be characterized by different expression of specific miRNAs. (PMID:24412053)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir26a-1	ENSMUSG00000065513

Paralogs (2): MIR26B (ENSG00000199121), MIR26A2 (ENSG00000207789)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.